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Vaccine Reports
Background: Immunization site pain is a common and unpleasant experi-
ence for both children and adults. It is a source of anxiety and distress and 
may ultimately result in nonadherence to vaccination schedules. There is lim-
ited information on how different brands of vaccines affect the intensity of 
immediate pain at the time of vaccine injection. 
Methods: Children in the United Kingdom (n = 178) were randomized 
to receive a booster dose of either the 10- or the 13-valent pneumococ-
cal conjugate vaccine (PCV-10 or PCV-13). Immediate immunization site 
pain was assessed using validated pain assessment tools and crying time 
to investigate factors that may interfere with parental compliance to vac-
cination.
Results: Pain measurements were available for n ≥ 74 and n ≥ 78 PCV-10 
and PCV-13 recipients, respectively. PCV-13 recipients had significantly 
higher scores on the observer-rated modified behavioral pain scale than did 
those receiving PCV-10. No significant differences in the induction of pain 
between the 2 vaccines were found when a parent-rated pain assessment 
tool or crying time was used.  
Conclusions: PCV-10 administration was associated with slightly less 
acute pain compared with the injection of PCV-13, but the size of the differ-
ence was small and is of unknown clinical significance.
Key Words: adverse event, acute pain, immunization site pain, pneumococ-
cal conjugate vaccine, children
(Pediatr Infect Dis J 2018;37:e103–e106)
Immunization site pain represents one of the most common com-plaints following vaccine administration.1 It is an unpleasant 
experience for both children and their parents and may contribute 
to needle phobia, anxiety, and distress associated with a health care 
provider’s appointment and may ultimately result in nonadherence 
to vaccination schedules.2,3
Although several previous vaccine trials have included 
immunization site pain as an adverse event following vaccina-
tion, different methods of assessment have been used. In 2012, 
the Brighton Collaboration published standardized criteria for 
the evaluation and reporting of immunization site pain allowing 
for comparability and uniform reporting of pain across different 
studies.4 Their recommendations include assessment tools for the 
evaluation of immediate pain following vaccination and, to the best 
of our knowledge, this is the first clinical vaccine trial in children 
using the approach suggested in this guideline. Very few studies 
have investigated the intensity of immediate pain and distress at the 
time of vaccine injection by evaluating different brands of vaccines. 
Immediate pain refers to the sensation of pain in response to vac-
cine administration at the vaccination site.4 Differences in imme-
diate pain at vaccination have been observed for different brands 
of the Measles, Mumps, and Rubella vaccine in 4 randomized 
controlled trials5–8 resulting in the suggestion of several national 
guidelines to use the least painful vaccine if more than 1 product is 
available and the products are interchangeable.9,10
There are 2 pneumococcal conjugate vaccines (PCVs) that 
are currently in use in national immunization schedules, that is, 
those containing 10 and 13 pneumococcal serotypes (PCV-10 and 
PCV-13), respectively. Both vaccines have been shown to effec-
tively protect against invasive pneumococcal disease when several 
doses are given to young children. Here, we report the investigation 
of immediate pain following booster vaccination of 12-month-old 
children with either PCV-10 or PCV-13 in a randomized vaccine 
trial. Pain during vaccine administration was studied using vali-
dated pain assessment tools and crying time to investigate factors 
that may interfere with parental compliance to vaccination. Target-
ing these factors in future vaccine trials with the aim of reducing 
immediate injection site pain might help decrease vaccine hesi-
tancy and hence improve immunization coverage.
METHODS
Immediate injection site pain was assessed as a second-
ary objective in a randomized vaccine trial involving healthy 
12-month-old children (n = 178).11,12 Ethical approval was obtained 
from the Oxfordshire Research Ethics Committee (11/SC/0473), 
and the study was registered on Clinicaltrials.gov (NCT01443416). 
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Children were randomized to receive a booster dose of either the 
10-valent PCV (PCV-10, Synflorix®, GSK Biologicals) or PCV-13 
(Prevenar 13®, Pfizer) following PCV-13 immunization at 2 and 4 
months of age. The primary objective of the study was the assess-
ment and comparison of the immunogenicity of the different vac-
cines, the results of which have been reported previously.11,12
Blood samples were taken immediately before vaccination at 
12 months of age, after which immediate pain at the time of injection 
was determined using validated pain assessment tools and crying 
time.4,13,14 As children 12 months of age are unable to articulate the 
degree of pain they experience, pain measurement was conducted 
on behalf of the children as suggested by the Brighton Collabora-
tion.4 As much time as possible (usually between 5 and 10 minutes) 
was allowed following drawing blood for the child to settle before 
the booster vaccine was given. As a possible confounding factor, 
“baseline mood” (with the reported dimensions “calm,” “crying,” or 
“distressed”) was recorded at the time of vaccination. Both vaccines 
were administered intramuscularly using a 0.6 × 25 mm 23-gauge 
needle into the anterolateral aspect of either thigh. The child sat in 
the parent’s lap and held securely by the parent by means of wrap-
ping 1 of the child’s arms around the parent’s waist and the parent 
holding the child’s other arms across the body and holding the legs. 
Vaccines were administered at room temperature.
The Modified Behavioral Pain Scale (MBPS, 0–10) was 
used to determine pain and was completed by a second member 
of the study team who did not administer the vaccine and was 
blinded to which vaccine was injected. The pain score assessors 
were specifically trained with an internal SOP using different vid-
eos showing children experiencing pain. Parents were asked to 
use the Numerical Rating Scale (NRS, 0–10) to estimate the pain 
intensity of their children. Finally, the duration of crying from the 
moment of needle insertion until all crying activity had ceased 
was recorded by study staff. Pain assessments were recorded on 
the diary card (Fig., Supplemental Digital Content 1, http://links.
lww.com/INF/C927).
Pain was compared between vaccine groups using an analysis of 
covariance (ANCOVA) adjusting for sex, age, ethnicity, baseline behav-
ior, site of injection, vaccinator, and the observer for MBPS (Table 1).
RESULTS
A total of 178 study participants were enrolled into the study, 
of which 87 and 90 received PCV-10 and PCV-13, respectively; 1 
study participant withdrew consent before vaccination.11 As there 
were several teams involved in the study, pain scores were randomly 
assessed by a total of 6 different people (Fig., Supplemental Digital 
TABLE 1. Summary Table for Immediate Pain at the Time of Immunization 
by Vaccine Group
 
PCV-13 PCV-10 ANCOVA 
Adjusted Group 
Effect* 95% CI PN (%) N (%)
MBPS     0.722 0.292–1.153 0.001
  0 0 (0) 0 (0)     
  1 0 (0) 0 (0)     
  2 0 (0) 0 (0)     
  3 1 (1.1) 2 (2.3)     
  4 2 (2.2) 1 (1.1)     
  5 1 (1.1) 4 (4.6)     
  6 11 (12.2) 15 (17.1)     
  7 18 (20.0) 23 (26.1)     
  8 21 (23.3) 15 (17.1)     
  9 17 (18.9) 8 (9.1)     
  10 8 (8.9) 6 (6.8)     
Total 79 (87.8) 74 (84.1)     
Missing 11 (12.2) 14 (15.9)     
Median (IQR) 8 (7–9) 7 (6–8)     
Mean (SD) 7.7 (1.5) 7.2 (1.5)     
NRS     0.532 ˗0.129, 1.19 0.114
  0 0 (0) 0 (0)     
  1 0 (0) 3 (3.4)     
  2 4 (4.4) 5 (5.7)     
  3 9 (10.0) 9 (10.3)     
  4 9 (10.0) 9 (10.3)     
  5 12 (13.3) 13 (14.9)     
  6 14 (15.6) 12 (13.8)     
  7 23 (25.6) 17 (19.5)     
  8 7 (7.8) 8 (9.2)     
  9 2 (2.2) 0 0     
  10 0 0 1 (1.1)     
Total 80 (88.9) 77 (87.5)     
Missing 10 (11.1) 11 (12.5)     
Median (IQR) 6 (4–7) 5 (4–7)     
Mean (SD) 5.6 (1.8) 5.3 (2.0)     
Crying time (sec)  4.31 ˗4.79, 13.42 0.350
N (mean) {SD} 
[min–max]
78 (41.0) {29.2}
[0–152]
74 (36.4) {21.5}
[0–97]
    
SD, standard deviation.
*Adjusted for sex, age, ethnicity, baseline behavior, site of injection, vaccinator (and observer for MBPS only).
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Content 2, http://links.lww.com/INF/C928), and, if a second person 
was not available, pain scores were not evaluated at all resulting in 
around 14% missing data, which were equally distributed between 
the groups (Table 1). The difference in pain scores between the PCV-
13 and PCV-10 groups did not vary between assessors.
Pain assessed by the MBPS was measured with a median score 
of 7 [interquartile range (IQR), 6−8] in the PCV-10 group and 8 (IQR, 
7−9) in the PCV-13 group (Table 1 and Fig. 1). None of the children in 
either group scored less than 3, and there were 29 (39%) and 46 (58%) 
study participants with scores of 8 or more following booster vaccina-
tion with PCV-10 and PCV-13, respectively (Table 1 and Fig., Sup-
plemental Digital Content 3, http://links.lww.com/INF/C929). MBPS 
scores in PCV-10 recipients were significantly lower than in PCV-13 
recipients although the overall difference between groups was only 
modest [adjusted group difference, 0.72 points in the MBPS; 95% 
confidence interval (CI), 0.29−1.15; P = 0.001; (Table 1 and Fig. 1)].
For the NRS assessed by a parent, median scores were 5 
(IQR, 4−7) and 6 (IQR, 4−7) in the PCV-10 and PCV-13 group, 
respectively (Table 1 and Fig. 2). The distribution of scores was 
similar in both groups, and only few participants (n = 9 in each 
group) were given scores of 8 and higher (Table 1 and Fig., Supple-
mental Digital Content 3, http://links.lww.com/INF/C929). There 
was no statistically significant difference between the groups for 
the NRS (adjusted group difference, 0.532; 95% CI, ˗0.13 to 1.19; 
P = 0.114; Table 1).
The duration of crying following vaccination ranged from 0 
to 152 seconds with no statistically significant differences between 
the 2 groups (Table 1 and Fig. 1). When adjusted for sex, age, eth-
nicity, baseline behavior, site of injection, and vaccinator, the over-
all crying time was no different in the PCV-13 compared with the 
PCV-10 group (adjusted group difference, 4.3 seconds; 95% CI, 
˗4.8 to 13.4; P = 0.35). However, the duration of crying across both 
groups was significantly lower when the child’s behavior before 
vaccination was judged by the observer as “calm” compared with 
“crying” (mean duration of crying for both groups: 35.5s versus 
55.1s; P = 0.011, data not shown). MBPS scores were also signifi-
cantly higher in “crying” children compared with “calm” children 
(mean MBPS 8.5 versus 7.2; P < 0.001, data not shown). No effect 
of baseline mood on parent-derived NRS was found (Fig., Supple-
mental Digital Content 4, http://links.lww.com/INF/C930).
DISCUSSION
By using validated assessment tools suggested by the 
Brighton Collaboration,4 we show that PCV-10 administration is 
associated with slightly less acute pain compared with the injection 
of PCV-13. This was demonstrated by significantly lower MBPS 
scores in PCV-10 compared with PCV-13 recipients.
In general, mean MBPS scores were high for both vaccines. A 
previous study similarly used MBPS for pain assessment in a vaccine 
FIGURE 1. Boxplots of pain assessment scores and crying time by vaccine group. P values are taken from ANCOVA. The 
median is shown as a line across the box (with the median value written above the line), and the box represents the lower 
and upper quartiles. Whiskers extend to the maximum or minimum values within 1.5 times the IQR above and below the 
third and first quartiles, respectively. Points outside this range are represented as dots.
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trial involving 2–6-month-old children who were given pentavalent 
routine vaccine (DTaP-Hib; Pentacel, Sanofi Pasteur) and 7-valent 
PCV (PCV-7; Prevnar, Wyeth).15,16 In that study, receipt of PCV-7 
was associated with significantly higher pain scores than DTaP-Hib 
(means 8.2 versus 6.3) suggesting that PCV-7 (the predecessor of 
PCV-13 and produced in a similar manner) is a more painful vaccine 
than other routine vaccines such as the DTaP-Hib vaccine.
There are limited data comparing immediate pain between 
different brands of similar vaccines and one can only speculate 
on the mechanisms that underlie pain responses at vaccine injec-
tion. The difference in pH of the injected material has previously 
been suggested as a possible explanation for the observed varia-
tion in pain using 2 measles-mumps-rubella vaccines.7,14 PCV-13 is 
slightly acidic than PCV-10 (5.8 versus 6.1), but other differences 
in the contents and physico-chemical properties of the 2 vaccines 
(Table, Supplemental Digital Content 5, http://links.lww.com/INF/
C931) may also affect the pain response. Needle size has previ-
ously been shown to affect reactogenicity following infant immu-
nization17 but whether it also affects pain responses during vaccine 
injection is unknown and may be a topic for further study.
As a limitation of the study, pain scores were assessed by several 
operators. Although the assessors were blinded to the vaccine given, 
videotaping the pain reaction and scoring afterward may be an alter-
native and possibly a more standardized approach. Pain scores were 
affected by the “mood” of the child following the blood draw and before 
vaccination. However, results are reported after adjusting for known 
confounders and given the design of the study, possible unknown con-
founders are likely distributed equally across the 2 groups.
In summary, we found that injection with PCV-13 induced sig-
nificantly more pain than injection with PCV-10 when assessed with 
a validated observed-rated pain tool; however, the size of the differ-
ence was small and is of unknown clinical significance. The number 
of vaccines that are recommended for infants has been increasing over 
the past 20 years. Factors that are associated with pain and distress 
following vaccination may interfere with parental compliance and add 
to the current upsurge of vaccine hesitancy. Therefore, evaluating and 
minimizing the factors that are associated with vaccination pain might 
improve tolerability of vaccines and hence vaccine acceptance.
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